drugset / Trial / NCT00401570
A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
Timeline
- Start
- 2005-03
- Primary completion
- 2008-06
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Volociximab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Volociximab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |